News for Pharmasset, Inc. - Google FinanceNews for Pharmasset, Inc. - Google FinancePharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th- September 17, 2008 Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th PR Newswire (press release) - 9 hours ago PRINCETON , NJ , Sept . 17 PRNewswire - FirstCall - - Pharmasset , Inc . ( NASDAQ : VRUS ) management will present at the UBS Global Life Sciences Conference being held from September 22 ...http://sev.prnewswire.com/infectious-disease-control/20080917/CLW00517092008-1.html Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2- September 9, 2008 Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 PipelineReview.com (press release) - Sep 9, 2008 PRINCETON , NJ , USA September 8 , 2008 Pharmasset , Inc . ( Nasdaq : VRUS ) announces the preliminary results of the fourth cohort of a 4 - week Phase 1 proof - of - concept clinical trial ...http://www.pipelinereview.com/content/view/21929/109/ Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2- September 8, 2008 Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders PR Newswire (press release) - Sep 8, 2008 PRINCETON , NJ , Sept . 8 PRNewswire - FirstCall - - Pharmasset , Inc . ( NASDAQ : VRUS ) announces the preliminary results of the fourth cohort of a 4 - week Phase 1 proof - of - concept ...http://sev.prnewswire.com/health-care-hospitals/20080908/CLM03508092008-1.html Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2- September 8, 2008 Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders PR Newswire (press release) - Sep 8, 2008 - 90% of genotype 2 or 3 patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable ...http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-08-2008/0004... Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences- September 7, 2008 Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences PR-USA.net (press release) - Sep 7, 2008 Pharmasset , Inc . management will present at the 3rd Annual Citi Biotech Day being held September 8 , 2008 , at the Citi Executive Conference Center , New York , NY.Management will also present ...http://pr-usa.net/index.php?option=com_content&task=view&id=130637&Itemid=30 Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences- September 5, 2008 Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences PR Newswire (press release) - Sep 5, 2008 PRINCETON , NJ , Sept . 5 PRNewswire - FirstCall - - Pharmasset , Inc . ( NASDAQ : VRUS ) management will present at the 3rd Annual Citi Biotech Day being held September 8 , 2008 , at the ...http://sev.prnewswire.com/infectious-disease-control/20080905/CLF05105092008-1.html |